Nova Patents
MX337361B

Transdermal drug delivery systems comprising a coated release liner.

Abstract

The present invention refers to a transdermal delivery device comprising a backing layer (11), at least one adhesive layer (12), and a release liner coated with a UV-cured highly crosslinked silicone (13). The present invention also refers to a method of preparing a transdermal delivery device comprising a backing layer (11), at least one adhesive layer (12), and a release liner coated with a UV-cured silicone (13).

MX337361B, drawing sheet 1
Sheet 1 of 67

Term

1.9 yearsleft in the term

Expires 28 August 2028.

  1. Priority
  2. Filed
  3. Granted
  4. Today
  5. Expires

10 claims: 2 independent, 8 dependent

  1. 1
    CLAIMS REIVINDICACIONES 1. Un dispositivo de liberación transdérmica que comprende una capa de protección, una capa adhesiva y un revestimiento de liberación cubierto con silicona curada con rayos UV, en donde dicha capa adhesiva contiene 39 por ciento en peso (%P) de un aceite mineral, 48%P de poliisobutileno (PIB), 8%P de un ingrediente farmacéutico activo y 5%P de dióxido de silicio coloidal (CSD). en donde dicho PIB de dicha capa adhesiva está en contacto con el revestimiento de liberación, y en donde dicho ingrediente farmacéutico es clonidina. one. A transdermal delivery device comprising a protective layer, an adhesive layer, and a release liner covered with UV-cured silicone, wherein said adhesive layer contains 39 weight percent (W%) of a mineral oil, 48% P of polyisobutylene (PIB), 8% P of an active pharmaceutical ingredient and 5% P of colloidal silicon dioxide (CSD). wherein said PIB of said adhesive layer is in contact with the release liner, and wherein said pharmaceutical ingredient is clonidine.
  2. 9
    A transdermal delivery device comprising a protective layer, an adhesive layer, and a release liner covered with UV-cured silicone. 9. Un dispositivo de liberación transdérmica que comprende una capa de protección, una capa adhesiva y un revestimiento de liberación cubierto con silicona curada con rayos UV. en donde el espesor de dicha cubierta de silicona curada con rayos UV varia aproximadamente de 2000 angstroms a aproximadamente 10,000. en donde de dicha capa adhesiva contiene un 39 por ciento en peso (%P) de un aceite mineral, 48%P de poliisobutileno (PIB), 5%P de dióxido de silicio coloidal y 8%P de un ingrediente farmacéutico activo, en donde dicho PIB de dicha capa adhesiva está en contacto con el revestimiento de liberación. wherein the thickness of said UV-cured silicone coating ranges from about 2000 angstroms to about 10,000. wherein said adhesive layer contains 39 percent by weight (% P) of a mineral oil, 48% P of polyisobutylene (PIB), 5% P of colloidal silicon dioxide and 8% P of an active pharmaceutical ingredient, in wherein said PIB of said adhesive layer is in contact with the release liner. en donde dicho ingrediente activo farmacéutico es clonidina, y wherein said active pharmaceutical ingredient is clonidine, and
Independent claims2